INTRODUCTION
The second messenger cyclic AMP (cAMP) is inactivated in cells through the action of cAMP phosphodiesterases (PDE), which effect its hydrolysis to 5'-AMP (Beavo, 1990 ). This activity is represented by a multigene family of enzymes having distinct characteristics (Beavo, 1990 ; Conti and Swinnen, 1990; Conti et al., 1991; Davis et al., 1990) . The type-IV PDE sub-family consists of a group of enzymes which specifically hydrolyse cAMP in a fashion which is insensitive to the addition of low concentrations of cyclic GMP (cGMP) and of Ca2+/calmodulin and whose members are specifically inhibited by the compound rolipram (Beavo, 1990) . The first of the type-IV PDEs to have been purified to apparent homogeneity and characterized were the peripheral-plasma-membrane PDE (rPPM-PDE) from rat hepatocytes (Marchmont et al., 1981) and a cytosolic PDE (dS-PDE) from dog kidney (Thompson et al., 1979) . These enzymes proved to be extremely difficult to purify, due not only to their paucity but also to their marked susceptibility to proteolysis and inherent lability; such factors have inhibited the characterization of all but a few type-IV PDEs. cDNAs for various type-IV PDEs have been isolated ; Conti and Swinnen, 1990; Conti et al., 1991) . This was done initially for the Drosophila dunc enzyme (Chen et al., 1986) . This cDNA was used as a probe to clone a series of type-IV isoforms from rat (Davis, 1990; Conti et al., 1990 Conti et al., , 1991 and from human cDNA libraries (Livi et al., 1990; Mchale et al., 1991; Bolger et al., 1993; Sullivan et al., 1994) . To date, however, no detailed effect of EDTA. h6. 1 was engineered to express a C-terminal fivehistidine motif (h6.1lhis5). This allowed purification of the PDE to apparent homogeneity in a simple two-step process involving a rolipram affinity column and a Ni2+-chelate column. A single monomeric protein of subunit molecular mass -73 kDa and native molecular mass -74 kDa resulted after a -53000-fold purification. This exhibited a Km for cAMP of 8 ,uM, a true Vm.ax of 0.8 ,tmol of cAMP hydrolysed/min per mg of PDE protein, a kcat of 3702 s-1, and a value of the specificity constant kcat./Km of 4.6 x 108 M-1 -s-1, the last implying a diffusion controlled reaction. Rolipram (K, 0.4 soluble; 0.7 ,uM pellet) and 3-isobutyl-1-methylxanthine (K, 15 soluble; 19 ,uM pellet) served as simple competitive inhibitors for both soluble and pellet forms of h6. 1, respectively. characterization oftype-IV PDEs ofhuman origin has been done, and no such species has been purified to apparent homogeneity.
We have described (Sullivan et al., 1994 ) the molecular cloning of a type-IV PDE, called hPDE-IVA.1h6.1 (h6. 1). This PDE is highly related to a type-IVA species reported previously by others (hPDE-IVA Livi et al., 1990 ), but differs with respect to five residues located within, or adjacent to, the putative catalytic domain (Sullivan et al., 1994) . These changes are Y317/D, R523/M, R527/P, E589/A and N598/S. The sequence of hPDE-IVAhol would appear, however, to reflect the native situation, with that of hPDE-IVA Livl (Livi et al., 1990) reflecting an aberrant form (see for discussion Sullivan et al., 1994) ; it is also possible that both these enzymes may reflect N-terminally truncated species (see Bolger, 1994 
Strains of Saccharomyces cerevisiae
The strains of S. cerevisiae used in this study are described in Table 1 . All yeast strains were constructed by standard genetic manipulations and were grown at 30°C in rich (YPD) medium, on complete (SC) medium lacking nutrients, or on YPD medium containing uracil and 5-FOA as specified (Sikorski and Boeke, 1991; Sullivan et al., 1994) .
Plasmids, DNA manipulations, and sequencing
The plasmid (pME69AAS) used to disrupt the ura3 gene in the pep4:: URA3 locus was constructed as follows. pME69, containing the ura3 gene on a HindIII fragment flanked by DNA from the pep4 gene locus, as used to disrupt the PEP4 gene previously (Sullivan et al., 1994) with the primers p13 and 3'Age. The 5' primer p13 (5'-ATGTGT-GACAAGCACACT-3') binds upstream of a unique BglII site in the 6.1 cDNA. The 3' primer 3'Age (5'-AGCTgtcgacGGA-ACCGGTAGGGTCTCCACC-3') primes at the extreme 3'-end of the 6.1 ORF. The PCR results in the loss of the stop codon of 6.1-and insertion of an AgeI site (upper case underlined) and -a SalI site (lower case underlined) at the extreme 3'-end in the sequence of the 3'Age primer given above. The PCR fragment was purified and digested with BglII and Sall to release a 665 bp fragment that was ligated into BamHI/SalI-digested p19MCS6 to create the plasmid pMCS6-Age. The plasmid pl9MCS6 is a derivative of pUC19 with different restriction sites in the multicloning region. The insert of pMCS6-Age was sequenced to ensure that no mutations had occurred. This plasmid was then digested with HindIII and EagI; the HindIll site lies in the vector next to the BamHI/BgilII fusion, whereas the EagI site lies within the insert, 128 bp upstream of the engineered AgeI site. The large HindlIl-EagI fragment was ligated with the 1.6 kb HindlIl-EagI fragment from YIpMSl-6.1 containing the glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter and the 5'-end of the ORF of 6.1. The insert of the resulting plasmid, pMCS6-GPD6. lAge, consisted of the GPD promoter fused to the entire ORF of 6.1, with the stop codon being replaced by the last three bases of the AgeI site. The large HindIII/AgeI insert from pMCS6-GPD6.lAge, consisting of the GPD promoter and the ORF of 6.1, was ligated to the large HindIII/AgeI fragment of pMCS9-3'(HIS)5 (see above) in order to create the plasmid pMCS9-GPD6.1(HIS)5. This contained the ORF of 6.1, one additional Gly codon, five His codons and a stop codon, and was flanked by unique BamHI and Sall sites at the 5'-and 3'-ends respectively. The BamHI-Sall fragment was ligated into Salll BamHI-digested YIpMSI to create YIpMSI-6.I(HIS)5.
PCRs (Saiki et al., 1988) were performed on plasmid DNA (1 ng) in 50 mM KCI/10 mM Tris/HCl (pH 8.3)/2 mM MgCl2 containing 200 ,uM each of the four deoxyribonucleotides, 0.1-0.5 ,uM of each oligonucleotide primer, 5 % formamide (Sarkar et al., 1990 ) and 2 units of Taq polymerase. After 20 cycles (each 30 s at 94°C, 1 min at 45°C, 1 min at 72°C) and then incubation at 72°C for 5 min, the reaction products were analysed by agarose-gel electrophoresis and DNA fragments were purified (Weislander, 1979) .
Sequencing was performed by the dideoxynucleotide chaintermination method (Sanger et al., 1977; Biggin et al., 1983; Chen and Seeburg, 1985) using T7 sequencing kits. The Bio-Rad gene pulser was used for transformation of yeast cells by electroporation (Becker and Guarente, 1991) . Verification of correct single integration and gene-replacement events was carried out by Southern analysis. Escherichia coli NM522 and K803 were used for plasmid transformation and propagation as previously described (Maniatis et al., 1982; Nishimura et al., 1990) .
Yeast cell culture and extraction Cells grown at 30°C in yeast-extract/peptone/dextrose medium were harvested some 20 h after inoculation with a starter culture (10 ml per 500 ml). Harvesting was achieved by centrifugation at 1400 g8V. for 15 min at 4 'C. Cell pellets (25 ml) were suspended by addition of 5 ml of 80 mM triethanolamine/HCl/5 mM MgCl2 buffer (adjusted to pH 7.4 with KOH) containing a mixture of protease inhibitors at a final concentration of 40 jtg/ml phenylmethanesulphonyl fluoride, 156 ,ug/ml benzamidine and 1 jug/ml each of aprotonin, leupeptin, pepstatin A and antipain. The protease inhibitors were initially dissolved as a 1000 x stock in 100 % dimethyl sulphoxide before addition to the buffer. The cells in the pellet were lysed by four passes through a French Pressure Cell Press (SLM Instruments Inc.; 40 ml cell) at 6624 kPa (960 lb/in2). The resultant lysate was centrifuged at 210000 gav for 45 min. Samples of both pellet and supernatant were assayed for PDE activity immediately and residual material was stored at -80 'C for later analysis. PDE assay PDE activity was assayed by a modification of the two-step procedure of Thompson and Appleman (1971) and Rutten et al. (1973) as described previously by Marchmont and Houslay (1980) . All assays were conducted at 30 'C, and in all experiments a freshly prepared slurry of Dowex/water/ethanol (1: 1: 1, by vol.) was used for determination of activities. Initial rates were taken from linear time courses of activity. For the determination of kinetic parameters, the PDE assays were conducted with [cAMP] over the range 0.1-100 ,uM. Double-reciprocal plot data were analysed by computer fitting to the hyperbolic form of the Michaelis-Menten equation by using an iterative least-squares procedure in order to obtain estimates of Km and associated errors (Ultrafit, Marquardt algorithm; Biosoft, Cambridge, U.K.). Dose-effect inhibitor analyses were performed with 3 #tM cAMP as substrate over a range of inhibitor concentrations as shown in the appropriate Figures. PDE inhibitors were dissolved in 100 % dimethyl sulphoxide as a 10 mM stock and diluted in 20 mM Tris/HCl/10 mM MgCl2 buffer at final pH 7.4 to provide a range of concentrations for use in the assay. The residual levels of dimethyl sulphoxide were shown not to affect PDE activity over the ranges used in this study.
Thermal denaturation
Pellet and soluble fractions were prepared as described above. Each sample was pipetted into pre-warmed 20 mM Tris/HCl/ 10 mM MgCl2, final pH 7.4, contained in a glass bijoux which had been placed on a stirrer in a water bath at the indicated temperature. At the time points shown on the appropriate Figure a 100 ,1 sample was removed and placed in an Eppendorf Microfuge tube, which had been kept on ice. PDE activities were then measured with 1 ,uM cAMP as substrate.
Purification of PDE activity from YMS8 yeast cells
Aminoalkyl-Sepharose 4B resin was substituted with the rolipram analogue AAL 115, which had been modified at the carboxyl end with 4-(3-carboxypropyloxy-4-methoxyphenyl)-2-pyrrolidine , as described by Fougier et al. (1986) . This was then used to bind h6.1hiS5 as described by Fougier et al. (1986) .
For a typical small-scale preparation a 50 % resin/water slurry (400,u) was first equilibrated for 1 h in 20 ml of TMD buffer (50 mM Tris/HCl, pH 7.5, 5 mM MgCl2 and 0.1 mM dithiothreiol). The resin was sedimented by centrifugation at 4000 gav and the supernatant removed. A soluble high-speed supernatant fraction from the disrupted YMS8 yeast cells (10 ml; as detailed above) was added to the resin and left, with mixing, at 30°C for 1 h, over which time the PDE activity bound to the resin. In practice, the amount of affinity resin used was that found to be sufficient to bind all of the PDE activity. Non-specifically bound proteins were removed by washing the resin with TMD buffer containing 500 mM KCI (30°C; 1 h). This was done by sedimenting the resin, as above, and resuspending it in 10 ml of the KC1/TMD buffer. PDE activity was then specifically eluted with TMD buffer containing 2 mM cAMP as described by Fougier et al. (1986) , i.e. for 1 h at 30 'C. The eluate was then mixed, for 1 h at 4 'C, with a Nickel ProBond Metal affinity-chromatography resin (400,ug of a 500% resin/20 % ethanol slurry) which had previously been equilibrated with TMD buffer. The resin, with adsorbed PDE, was washed by first sedimenting the resin and then resuspending it in 10 ml of TMD buffer containing 500 mM KCI at 4 'C (1 h) in order to remove any non-specifically adsorbed proteins. This was repeated at least three times or until no 280 nm-absorbing material was eluted. PDE activity was then eluted from the resin (1 h at 4°C) with a minimal volume (1 ml) of TMD buffer containing 50 mM EDTA. After recovering the supernatant (1 ml), 250,u1 of 1 M MgCl2 was added and the sample was stored frozen, in batches, until required.
Protein determination
Protein was routinely measured by the method of Bradford (1976) , with BSA as a standard. The assessment of protein concentration in the final purified PDE preparation was determined by subjecting samples to SDS/PAGE on a 10% gel, followed by silver staining. Standard samples of BSA (0.005-0.2,ug) were run on separate lanes on the same gel. The gel was then scanned while wet in a Shimadzu CS-9000 dual-wavelength flying-spot scanner at a wavelength of 575 nm. A linear relationship was found between absorbance and applied protein over the range examined. This allowed us to construct a calibration curve from which the protein content of the applied PDE fraction was determined relative to BSA as a standard.
Molecular-mass determination by SDS/PAGE
Purified PDE samples were freeze-dried and resuspended in onetenth of their original volume. Samples (50,ul) were boiled in an equal volume of sample buffer (125 mM Tris/HCl, final pH 6.8, 25 % glycerol, 4 % SDS and 5 % 2-mercaptoethanol) for 5 min. The samples were subjected to SDS/PAGE at 60 mA through a 10 % gel as described by Laemmli (1970) . Further samples containing prestained molecular-mass markers (200, 97.4, 68, 43, 29, 18.4 and 14.3 
RESULTS

Disruption of URA3
The strain YMS5 is a derivative of YMS4, which had been selected for loss of functional ura3 gene product by counterselection on media containing 5-FOA (Sullivan et al., 1994 Figure 2 ) before removal of material to ice as a prelude to performing an assay to determine the residual PDE activity in these fractions. Semi-log plots were made of log of percentage of PDE activity remaining against time, from which the half-life of decay (t05) was determined. Dose-dependent changes in activity with Mg2+ and Mn2+ and EDTA were done in the presence of 3 ,uM cAMP as substrate by using procedures described in the legend to Figure 6 . K, values for rolipram and IBMX were determined from both slope and Dixon (1953) replots of data generated as shown in Figures 3 and 5. K/ values for Ro-20-1724 and for cilostimide were calculated by using the dose-response data generated in Figure 4 on the basis that these inhibitors were competitive in action. Re-activation is for EDTA inactivated enzyme. Experiments were done with n separate enzyme preparations, with assays done in triplicate in each case. Values are means + S.D; n.d., not determined.
Parameter Soluble form Pellet form
Km for cyclic AMP (,uM) 4.1 + 1.7 (n = 6) 5.2+1 .5 (n = 6) K; for rolipram (,uM) PDE activity in the strain YMS8, which contained a single copy of the h6.1 cDNA tagged to express the enzyme with five histidine residues at its C-terminus (h6.lhis5), was also cAMPspecific. It was similarly typical of a type-IV PDE (see above), with an activity of 2-6 pmol of cAMP hydrolysed/min per mg of protein seen in soluble extracts (range; n = 16). Activity was found in both the soluble fraction of the yeast homogenate (25-33 %) as well as in the pellet fraction (range; n = 16).
Purification of h6.1A5
This was performed as described in the Materials and methods section by applying a two-stage affinity-column procedure to a soluble extract (210000 g/45 min supernatant) from the strain YMS8. The first stage involved the use of a rolipram affinity column, which effected a purification of -160-fold with a 20-25 % yield. The second stage utilized a Ni2l column, which effected an overall purification of -553000-fold with an overall yield of 5-10 %. The PDE produced was apparently homogeneous by virtue of it giving a single protein band which comigrated with activity on non-denaturing gels (results not shown) and a single silver-stained band of 73 + 2 kDa on SDS/PAGE (Figure la). (Figure lb ) of the homogeneous enzyme purified from YMS8 indicated a native molecular mass of 74 + 3 kDa. Similar results were found for the single peak of soluble PDE activity occurring in the crude soluble fraction from YMS8 (76 + 2 kDa) and for the single peak of activity found by using the crude soluble fraction from YMS6 (73 + 3 kDa). h6.1 thus appears to be a monomeric protein, and the addition of five histidine residues at its C-terminus does not appear to alter this.
Molecular size Gel filtration
That single peaks of PDE activity were observed in analyses done on the crude soluble extracts is consistent with their being a single homogeneous population of soluble h6. 1 expressed. This is consistent with the thermostability studies (see below).
Thermostability of yeast-expressed h6.1 PDE
The thermostability of h6. 1 PDE activity (YMS6) found in both the soluble and pellet fractions was assessed. In each instance, activities decayed as a single exponential, yielding linear semi-log 45°C and 50°C (Figures 2a and 2b) . The activity in the pellet, however, was considerably more thermostable than that in the soluble fraction (Figures 2a and 2b ; Figures 3 and 4) and Ro-20-1724 (Table 2 ; Fig. 4) . It was also inhibited by the non-selective PDE inhibitor IBMX and, at much higher concentrations, by the typeplots of residual activity against time for studies done at both Shown is the inhibitory effect of IBMX on h6.1 in these typical experiments done at least three times. In (a) are double-reciprocal plots of cAMP hydrolysis against [cAMP] , and in (b) are replots of their slopes against [IBMX] . Dixon (1953) Figure 4 ). This profile is typical for a type-IV PDE activity (Houslay and Kilgour, 1990; Conti and Swinnen, 1990; Conti et al., 1991) .
Kinetics of inhibition of rolipram and IBMX
Both rolipram ( Figure 3 ) and IBMX ( Figure 5 ) acted as simple competitive inhibitors of h6.1 activity expressed in both the soluble and the pellet fractions of YMS6. This was evident from the fact that double-reciprocal plots of PDE activity against cAMP concentrations remained linear over a wide range of substrate and inhibitor concentrations, and that both the slope and Dixon (1953) Action of EDTA and the bivalent cations Mg2+ and Mn2+ Addition of either Mg2`or Mn2+ to PDE assays of h6. 1 led to a dose-dependent increase in activity (Figure 6a ). In contrast, addition of the chelating agent EDTA either to assays or directly to h6.1 caused the dose-dependent abolition of PDE activity (Figure 6b ). However, in both instances, the inhibitory effect of EDTA could be simply reversed by addition of either Mg2+ or Mn2+ to h6.1 (Figure 6a ). DISCUSSION h6.1 is clearly a type-IV PDE in that it specifically hydrolyses cAMP, is unaffected by Ca2+/calmodulin and by low concentrations of cGMP, and is potently inhibited by the selective inhibitors rolipram and Ro-20-1724 (Table 2) . It also shares sequence similarity with the various type-IV PDEs cloned from rat, in particular RDI (the rat brain rolipram-sensitive form), which would indicate that it can be classified as a PDE-IVA species (Sullivan et al., 1994) .
In order to purify h6. (-6.6 x I0O M-1 * s-') and also for dS-PDE (1.6 x 108 M-1 -s-1).
The similarity of these specificity constants would support the contention made in each case that such enzymes were purified to apparent homogeneity. h6. 1 in both soluble and pellet forms (Table 2) in yeast, as well as when expressed in soluble forms in COS-1 cells (Sullivan et al., 1994) , showed not only similar Km values for cAMP hydrolysis but also similar K1 values for inhibition by rolipram. This indicates that, whatever gives rise to the aggregated form of h6. 1 in yeast, the catalytic/inhibitor-binding site would appear to be relatively unaffected. Indeed, the only obvious difference between the pellet and soluble forms was that the pellet form was considerably more thermostable (Table 2) . Presumably this was because the formation of the immobilized material constrained the conformation of the enzyme such that it resisted thermal denaturation. As with the soluble enzyme, thermal denaturation allowed all (> 90%) of the pellet activity to decay as a single exponential (Figure 2 ). This is characteristic of a single homogeneous population of enzyme molecules in both instances. Soluble h6.1 in yeast is not then formed from a mixture of partially degraded proteins. This is consistent with the fact that h6. Ihis5 can be purified to yield a single protein of the size predicted from its sequence and that gel-filtration studies identified a single peak of activity (Figure 1 ). The soluble form presumably reflects the native state, as h6. 1 activity expressed in transfected COS cells is found exclusively in the cytosol (Sullivan et al., 1994 Bergstrand et al., 1978; Grant and Colman, 1984; Lavan et al., 1989) . However, although two rolipram-inhibited type-IV PDEs in hepatocytes are clearly activated by these bivalent cations in a dose-dependent fashion (Lavan et al., 1989) , a soluble cAMP-specific PDE (type VII) has also been identified in hepatocytes which appears to be insensitive to activation by Mg2+ and also inhibition by IBMX (Lavan et al., 1989 There has been allusion to the possibility that the mechanism of inhibition of type-IV PDEs by rolipram may be anomalous, on the basis that log dose-inhibition curves showed a shallow profile (McLaughlin et al., 1993; Bolger et al., 1993) and that inhibition data in double-reciprocal plots of studies done on hPDE-IV A Livi did not appear to fit simple competitive kinetics (Livi et al., 1990) . However, no rigorous analysis of inhibition of a type-IV PDE by either a selective inhibitor such as rolipram or a non-selective inhibitor such as IBMX has been reported before the present study. We show here that both compounds serve as simple competitive inhibitors of h6. 1, yielding linear doublereciprocal plots, linear slope replots and linear Dixon (1953) replots (Figures 3 and 5) .
In analyses of a human type-IVA PDE, Torphy and coworkers (Livi et al., 1990; Torphy et al., 1992) noted that rolipram did not serve as a simple competitive inhibitor. They observed that the change in slope of double reciprocal plots of rolipram inhibition deviated from that which could be predicted for simple competitive kinetics. It appeared that the value for the slope was lower than that expected. Certainly our formulation of slope replots (data not shown) from data ( fig. 5 of Livi et al., 1990; fig. 3 of Torphy et al., 1992) would support this, in that such plots were markedly concave in form. These anomalies would not be expected if the enzyme bound more that one molecule of rolipram as convex slope replots would typify this, with a slope being observed which was bigger than that expected for simple competitive inhibition. The data describing the type-IVA PDE analysed by Torphy and co-workers (Livi et al., 1990; Torphy et al., 1992) appear to indicate that rolipram serves as a partial competitive inhibitor of that enzyme (see Dixon and Webb, 1979) . Consistent with such a mechanism, we noted (results not shown) that a secondary replot of the reciprocal of the change in slope against the reciprocal of [rolipram] was linear (see Dixon and Webb, 1979) . From such an analysis we could directly calculate a value of 1.8 ,uM for the affinity constant K1', which reflects the binding of rolipram to the enzymesubstrate complex of hPDE-IVA LiVi* The application of curvefitting strategies to this secondary replot then allowed us to determine values for KiroliPram as 0.24 ,uM and for K.cAMP as 5 ,uM.
These observations suggest that the amino acid differences between hPDE-IVA h6.1 and hPDE-IVA Livi do indeed lead to a functional alteration. This may be because such residues are all located either in or near to the domain of the enzyme which is believed to contain the catalytic site (Chen et al., 1986; Jin et al., 1992) . The different inhibitory kinetic mechanisms for the action of rolipram on these two type-IVA PDEs suggests that h6. 1 and hPDE-IVA-Livi are conformationally and functionally distinct forms. One explanation for the difference in kinetics between the two closely related PDEs would be that the active site in hPDEIVATLivi has been distorted, compared with h6. 1, such that it can now accommodate both cAMP and rolipram together. Clearly, confirmation of this will involve independent approaches, such as the structural analysis of these enzymes. However, it is clear from the diverse nature of the range of PDE inhibitors identified (see, e.g., Weishaar et al., 1985) Although the paucity and lability of PDEs, especially from human sources, has severely constrained the development of our understanding of members of this important enzyme family, the availability of cloned enzymes which can be efficiently expressed in yeast should help to resolve this.
